| dbo:abstract |
Omigapil (TCH346 or CGP3466) is a drug that was developed by Novartis and tested in clinical trials for its ability to help treat Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS). The development for PD and ALS have been terminated due to lack of benefit, but Santhera Pharmaceuticals bought the compound for development for the treatment of congenital muscular dystrophy (CMD). Omigapil was first synthesized at Ciba-Geigy, Basel, Switzerland. Santhera Pharmaceuticals has since taken over production of omigapil and preclinical trials for CMD. In May 2008, omigapil was granted orphan designation to commence clinical trials for. Pharmacokinetic trials are scheduled to commence enrollment in the second half of 2012 to determine the appropriate pharmacokinetic profile of the drug for children with laminin-α2-deficient congenital muscular dystrophy (MDC1A) and collagen VI related myopathy. Santhera Pharmaceuticals will use the phase 1 clinical trial to determine if the drug is safe and acts with the same pharmacokinetic profile in children as it does in adults. The impending clinical trial will take place in the United States at the National Institute of Neurological Disorders and Stroke/National Institute of Health(NNDCS/NINDS) (Bethesda, Maryland) and in the United Kingdom at Great Ormond Street Hospital (UCL). (en) |
| dbo:casNumber |
181296-84-4 |
| dbo:fdaUniiCode |
5V14HD0N4Q |
| dbo:pubchem |
6419718 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Omigapil_skeletal.svg?width=300 |
| dbo:wikiPageExternalLink |
http://www.santhera.com/index.php |
| dbo:wikiPageID |
3139976 (xsd:integer) |
| dbo:wikiPageLength |
20460 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1123038405 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Rotenone dbr:Blood_brain_barrier dbr:Pharmaceutical_drug dbr:Ubiquitin_ligase dbr:Dopaminergic dbr:In_vitro dbr:In_vivo dbr:P53 dbr:Molar_concentration dbr:Monoamine_oxidase_inhibitor dbr:Congenital_muscular_dystrophy dbr:Apoptosis dbr:MPTP dbr:Subcutaneous_injection dbr:Clinical_trial dbr:Agrin dbr:Laminin dbr:Nitrosylation dbr:P21 dbr:Amyotrophic_lateral_sclerosis dbc:Drugs_acting_on_the_nervous_system dbc:Orphan_drugs dbc:Propargyl_compounds dbr:Basement_membrane dbr:Nitric_oxide_synthase dbr:Novartis dbr:Oxidopamine dbr:Parkinson's_disease dbr:Ciba-Geigy dbr:Glyceraldehyde_3-phosphate_dehydrogenase dbr:Kainate_receptor dbr:P53_upregulated_modulator_of_apoptosis dbr:AMPA_receptor dbr:Acetyltransferase dbr:Ketamine dbr:Lactacystin dbr:Bioavailability dbr:Biomarker dbr:Collagen_VI dbr:Axotomy dbr:Pharmacokinetic dbr:Dose-response_curve dbr:Cytosine_arabinoside dbr:Methamphetamine dbr:Neuroblastoma dbr:Neuronopathy dbr:Cerebellar_granule_cell dbr:Selegiline dbr:Oligodendrocyte dbr:Tricyclic dbr:Excitotoxicity dbr:Myopathy dbr:NMDA_receptor dbr:Motor_neuron dbr:SIAH1 dbr:Maleate dbr:Mesencephalic dbr:Laminin-α2 dbr:Neuroprotective dbr:P300/CBP dbr:PC12_cell dbr:File:Omigapil_Mechanism_of_Action.png dbr:Floppy_infant_syndrome dbr:Nigrostriatal dbr:Signaling_cascade dbr:Muscle_fiber dbr:Rhesus_monkey dbr:Peripheral_nerves dbr:Glycolytic dbr:Proapoptotic dbr:Demyelination dbr:Β-amyloid |
| dbp:atcPrefix |
None (en) |
| dbp:c |
19 (xsd:integer) |
| dbp:casNumber |
181296 (xsd:integer) |
| dbp:chemspiderid |
4925351 (xsd:integer) |
| dbp:h |
17 (xsd:integer) |
| dbp:iupacName |
Dibenzo[b,f]oxepin-10-ylmethyl-methyl-prop-2-ynylamine (en) |
| dbp:legalStatus |
Investigational (en) |
| dbp:n |
1 (xsd:integer) |
| dbp:o |
1 (xsd:integer) |
| dbp:pubchem |
6419718 (xsd:integer) |
| dbp:smiles |
C=3c1ccccc1Oc2ccccc2C=3CNCC#C (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
QLMMOGWZCFQAPU-UHFFFAOYSA-N (en) |
| dbp:synonyms |
TCH346, CGP3466B (en) |
| dbp:unii |
5 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:Cite_journal dbt:Drugbox dbt:Reflist dbt:Short_description |
| dcterms:subject |
dbc:Drugs_acting_on_the_nervous_system dbc:Orphan_drugs dbc:Propargyl_compounds |
| gold:hypernym |
dbr:Drug |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatOrphanDrugs yago:Agent114778436 yago:CausalAgent100007347 yago:Drug103247620 yago:Matter100020827 yago:PhysicalEntity100001930 dbo:Drug yago:Substance100020090 yago:WikicatDrugsActingOnTheNervousSystem |
| rdfs:comment |
Omigapil (TCH346 or CGP3466) is a drug that was developed by Novartis and tested in clinical trials for its ability to help treat Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS). The development for PD and ALS have been terminated due to lack of benefit, but Santhera Pharmaceuticals bought the compound for development for the treatment of congenital muscular dystrophy (CMD). (en) |
| rdfs:label |
Omigapil (en) |
| owl:sameAs |
freebase:Omigapil yago-res:Omigapil wikidata:Omigapil dbpedia-fa:Omigapil dbpedia-sh:Omigapil dbpedia-sr:Omigapil https://global.dbpedia.org/id/4sbvm |
| prov:wasDerivedFrom |
wikipedia-en:Omigapil?oldid=1123038405&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Omigapil_Mechanism_of_Action.png wiki-commons:Special:FilePath/Omigapil_skeletal.svg |
| foaf:isPrimaryTopicOf |
wikipedia-en:Omigapil |
| is dbo:wikiPageRedirects of |
dbr:CGP3466B dbr:TCH346 |
| is dbo:wikiPageWikiLink of |
dbr:Amyotrophic_lateral_sclerosis_research dbr:Management_of_Parkinson's_disease dbr:Parkinson's_disease_clinical_research dbr:CGP3466B dbr:TCH346 |
| is foaf:primaryTopic of |
wikipedia-en:Omigapil |
